Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Merrill Cuts Genzyme General to 'Near-Term Buy'

Merrill Lynch downgraded Genzyme General (GENZ) to near-term and long-term buy from strong buy.

Analyst Eric Hecht says guidance was lowered due to significantly lower than expected Renagel sales. He says the news follows published guidance for 2002 about a month ago. He thinks some type of change in manufacturing of Renagel, and a desire to lower inventory levels from 12 to six weeks may have occurred since the company's last guidance.

Hecht says he believes momentum in Renagel about to slow down a bit, although the company still is reiterating its $260 million to $280 million 2002 guidance. He notes Genzyme also is keeping its 25% 2002 earnings per share growth forcast. Hecht sees $1.44 2002 EPS, and $1.75 for 2003.

blog comments powered by Disqus